Leukemia Home > Safety and Efficacy of Campath

Campath® (alemtuzumab) is a prescription drug approved to treat a certain type of leukemia known as B-cell chronic lymphocytic leukemia (B-CLL). It belongs to a group of medicines known as monoclonal antibodies.
In a clinical study examining the efficacy of Campath, the drug was shown to extend the period of time leukemia does not progress, more so than chlorambucil (Leukeran®), another leukemia medicine. In the study, people who received Campath went about 14.6 months without their condition getting worse, compared with 11.7 months in people taking chlorambucil.
Campath is a relatively safe medication, although some sort of side effect can be expected. Common reactions include low blood cell counts and fever. Fortunately, such problems are often mild and easily treated.
(Click Campath to learn more about this drug's safety and efficacy, as well as dosing guidelines, what to do in cases of overdose, and more.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):



Related Channels

eMedTV Links
Copyright © 2006-2018 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.